Pelosi Roasts a 75% Healthcare Portfolio Missing Major Tech Gains

I always appreciate an investor who brings a clear, unified agenda to the table. Reviewing this portfolio, however, I am struck by the distinct impression that I am not looking at a diversified wealth-building vehicle, but rather a lobbyist’s briefing binder for the Health and Human Services subcommittee.

It is impeccably organized, meticulously researched, and entirely one-dimensional.

Paul and I have always believed that wealth creation requires a profound, unwavering faith in American innovation. You clearly share this faith, but you have applied it so narrowly that one must wonder if you are wearing blinders. Investing is quite similar to drafting effective legislation: it requires coalition building across multiple sectors to ensure long-term stability and success. You have gathered an impressive caucus of pharmaceutical executives, but you have left the rest of the American economy waiting in the lobby. Let us review the fundamentals together, shall we?

When I look at your asset allocation, the conviction is immediately apparent—and conviction is a quality I respect deeply. I do not sign legislation I am not committed to, and one should not allocate capital without similar resolve. You have dedicated an overwhelming 75% of your capital directly to the healthcare sector, anchoring this with a 15.7% allocation to a broad market healthcare ETF.

Your proprietary research into the GLP-1 weight-loss and diabetes market is evident and commendable. Holding substantial, double-digit positions in Eli Lilly and Novo Nordisk demonstrates that you pay very close attention to demographic trends and intangible assets—which correctly make up nearly half of your portfolio's competitive moat profile. You have also wisely anchored these growth engines with steady, scale-advantaged providers like UnitedHealth Group.

I note your cash reserves sit at a modest 6.9%. In my experience, a portfolio requires strategic dry powder. When the right opportunity presents itself—and it always does, provided you are doing your homework—you need to be ready to act decisively. This is a respectable reserve, though sitting idle is a failure of due diligence if prolonged. You are properly positioned globally, with over 70% in North America and a measured 17% exposure to European markets, ensuring you capture the best of global biopharma innovation. However, a portfolio is defined just as much by what it omits as by what it includes.

While your healthcare thesis is well-researched, your broader strategic vision suffers from severe tunnel vision. A seasoned investor must align their capital with the full spectrum of public policy tailwinds.

🚩 A Complete Absence of American Technology: This is, quite frankly, staggering. NVIDIA, Broadcom, and the broader semiconductor complex are the foundational architecture of modern American economic leadership. A portfolio without any meaningful exposure to artificial intelligence, cloud computing, or cybersecurity at this stage suggests you have simply not been paying attention to the fundamental realities of the global economy.

🚩 Ignoring Legislative Catalysts: You understand healthcare policy, but you have entirely ignored the transformative legislative achievements driving other sectors. The CHIPS and Science Act, sweeping infrastructure investments, and clean energy initiatives are providing unprecedented structural tailwinds. An investor who ignores this policy environment is flying blind.

🚩 Redundant ETF Allocation: You hold nearly 16% in a broad healthcare ETF (XLV), while simultaneously maintaining massive concentrated positions in the exact same companies (UnitedHealth, Eli Lilly, Thermo Fisher) that dominate that index. This is not diversification; it is administrative redundancy. It ties up capital that could be deployed into other sectors.

🚩 No Downside Protection: With over 90% of your equity effectively tied to the regulatory approvals and clinical trial outcomes of a single sector, you are carrying massive idiosyncratic risk. Sophisticated investors use all available instruments, including structured options, to protect their downside. Simply holding and hoping the FDA remains favorable is not a risk management strategy.

I rate this portfolio a 4 out of 10. It is fundamentally sound in its specific stock selection, but strategically compromised by its terrifying lack of sector diversification. While this allocation easily passes the Health subcommittee, it fails to reach the House floor due to a profound lack of broader technological infrastructure.

To amend this portfolio, I suggest the following actionable steps:

1. Liquidate the Redundancy: Reallocate the 15.7% held in the healthcare ETF. You already own the best-in-class companies individually; you do not need to pay an expense ratio to hold the laggards.

2. Establish a Technology Anchor: Deploy your newly freed capital—and perhaps a portion of your 6.9% cash reserve—into the semiconductor and enterprise software sectors. You must capture the compounding growth of American tech innovation.

3. Broaden Your Policy Exposure: Look toward industrials, cybersecurity, or clean energy infrastructure. Align your capital with the broader macroeconomic agenda.

4. Implement Risk Management: Given your deep exposure to clinical trial risks and patent cliffs, consult with your advisors about utilizing options to hedge against sudden regulatory shocks.

As I have often said, uncertainty is not a reason to do nothing—it is a reason to do the right thing. Pay closer attention to the fundamentals driving the rest of the American economy, and your portfolio will yield far more resilient results.